Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | NCF1 | P14598 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22519024 | 0.94 | L3MBTL1 (0.41) | L3MBTL1L3MBTL3PIM1HRH3KDM4E | |
| SCHEMBL15217801 | 0.92 | L3MBTL1 (0.36) | L3MBTL1L3MBTL3PIM1HRH3KDM4E | |
| SCHEMBL18563138 | 0.92 | KDM4E (0.38) | L3MBTL1L3MBTL3PIM1HRH3KDM4E | |
| SCHEMBL3436969 | 0.91 | L3MBTL1 (0.46) | L3MBTL1L3MBTL3PIM1HRH3KDM4E | |
| SCHEMBL12772837 | 0.91 | L3MBTL3 (0.46) | L3MBTL1L3MBTL3PIM1HRH3KDM4E | |
| SCHEMBL736095 | 0.89 | KDM4E (0.47) | L3MBTL1L3MBTL3PIM1HRH3KDM4E | |
| SCHEMBL1646548 | 0.89 | KDM4E (0.47) | L3MBTL1L3MBTL3PIM1HRH3KDM4E | |
| SCHEMBL82229 | 0.89 | KDM4E (0.50) | L3MBTL1L3MBTL3PIM1HRH3KDM4E | |
| SCHEMBL736305 | 0.89 | KDM4E (0.47) | L3MBTL1L3MBTL3PIM1HRH3KDM4E | |
| SCHEMBL26180991 | 0.89 | ALDH1A1 (0.36) | L3MBTL1L3MBTL3PIM1HRH3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 257 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3402791-A1 | SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2018-11-21 | — | — | EP | claimed |
| US-10000502-B2 | Substituted thiohydantoin derivatives as androgen receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-19 | — | — | US | claimed |
| US-20170233401-A1 | SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-17 | — | — | US | claimed |
| WO-2017123542-A1 | SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-20 | — | — | WO | claimed |
| EP-1753743-B1 | PYRIDAZINONE DERIVATIVES, METHODS FOR PRODUCING THEM AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2015-03-04 | — | — | EP | claimed |
| US-7709466-B2 | Pyridazinone derivatives, methods for their production and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | claimed |
| US-20070088041-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-04-19 | — | — | US | claimed |
| EP-1753743-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR PRODUCING THEM AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis Deutschland GmbH (DE) | 2007-02-21 | — | — | EP | claimed |
| WO-2005111018-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR PRODUCING THEM AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-11-24 | — | — | WO | claimed |
| EP-3556758-B1 | 1,2-DIHYDRO-1,6-NAPHTHYRIDIN-2-ONE DERIVATIVES AS CDK4/6 INHIBITORS | CSTONE PHARMACEUTICALS SUZHOU CO LTD (CN) | 2024-07-17 | — | — | EP | disclosed |
| EP-3816164-B9 | ISOTHIAZOLO[5,4-D]PYRIMIDINE COMPOUND AS IRAK4 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2024-07-10 | — | — | EP | disclosed |
| WO-2024123991-A1 | TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | POSEIDON INNOVATION 1, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024123999-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | POSEIDON INNOVATION 1, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| EP-4076650-B1 | 3-(5-METHOXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2024-02-28 | — | — | EP | disclosed |
| US-7176313-B2 | Anti acid-fast bacterial agent containing pyridonecarboxylic acids as active ingredient | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-7176313-B2 | Anti acid-fast bacterial agent containing pyridonecarboxylic acids as active ingredient | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| EP-1740579-A1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | Abbott Laboratories (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005111018-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR PRODUCING THEM AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005095387-A1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233401-A1 | SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | AR, SHBG, NR5A1 | L3MBTL1 2252/4885L3MBTL3 3031/4885PIM1 4472/4885 |
| US-10000502-B2 | Substituted thiohydantoin derivatives as androgen receptor antagonists | AR, SHBG, NR5A1 | L3MBTL1 2252/4885L3MBTL3 3031/4885PIM1 4472/4885 |
| US-20070088041-A1 | PYRIDAZINONE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS | GSK3B, GSK3A, PDXK | L3MBTL1 4412/4885L3MBTL3 3901/4885PIM1 1065/4885 |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | L3MBTL1 3013/4885L3MBTL3 2990/4885PIM1 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.